MEDISAPIENS OY

Their core work

MEDISAPIENS OY is a Finnish health data technology company specializing in big data platforms for hematological cancer research. Their core contribution is building and operating infrastructure that aggregates real-world patient data across hospital networks — turning fragmented clinical records into analyzable datasets for rare blood cancers including leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma. They sit at the intersection of clinical informatics and oncology research, translating raw patient outcomes into structured evidence that pharmaceutical companies and clinical researchers can use to understand disease trajectories and treatment effectiveness. As their work has matured, they have moved toward defining business models around digital health outcomes, suggesting they are commercializing their data platform beyond the research context.

What they specialise in

How they've shifted over time

Their participation began in 2017 with a clear focus on data collection and disease classification — building a platform around specific cancer types (leukemia, lymphoma, MDS, multiple myeloma) and capturing real-life patient outcomes. By 2020 and the HARMONY PLUS phase, the disease-specific framing gives way to broader analytical and commercial language: translational medicine, molecular genetics, myeloproliferative and lymphoproliferative disorders as disease families rather than individual conditions, and explicitly a business model for digital health outcomes. The trajectory is from platform-builder for researchers toward a commercially viable health data product with defined monetization logic.

MEDISAPIENS appears to be transitioning from a research infrastructure contributor toward a commercial digital health data company — a future collaboration could benefit from their platform capabilities as much as their clinical domain expertise.

How they like to work

MEDISAPIENS participates exclusively as a consortium member and has never coordinated an H2020 project, indicating they are comfortable operating as a specialist contributor within larger alliances. Both projects belong to the same HARMONY initiative — a pan-European alliance with dozens of partners — meaning their entire EU research experience is within one extended collaboration rather than across diverse consortia. This suggests they bring a deep, sustained contribution to a single large network rather than broad partnership diversity.

MEDISAPIENS has worked alongside 57 unique partners across 13 countries, all through the HARMONY ecosystem — one of the largest hematology data alliances in Europe. Their network is densely European and clinical in character, dominated by hospitals, cancer registries, and pharmaceutical partners.

What sets them apart

MEDISAPIENS is a rare example of a small Finnish SME embedded deeply in a pan-European clinical oncology data consortium, contributing technology infrastructure rather than research capacity. Their specific value is in handling the data engineering and platform side of hematological cancer studies — a role that most academic partners cannot fill and most large IT companies do not specialize in. For a consortium needing real-world evidence infrastructure for rare blood cancers, they offer both technical capability and established relationships within the HARMONY clinical network.

Highlights from their portfolio

• HARMONY
  The flagship project — a large-scale EU hematology data alliance covering seven cancer types with real-world patient data, representing the largest share of MEDISAPIENS' EU funding (€145,466) and running for six years (2017–2023).
• HARMONY PLUS
  The successor project extending the platform into molecular genetics and commercial digital health outcomes, signaling MEDISAPIENS' pivot toward a sustainable business model around their data infrastructure.